Columbia, MD – (May 18, 2015) – ACell, Inc. today announced the selection of Elizabeth Smith as Senior Director, Clinical Research. In this role, Smith will lead all ACell clinical research initiatives and offer strategic direction for the company’s research activities.
“Elizabeth has a proven track record of effectively leading clinical teams,” said James A. D’Orta, MD, Chief Executive Officer. “As ACell continues to grow and help more patients in expanding therapeutic areas, our clinical research program will be an essential driver for regulatory approvals, secure reimbursement, and post-market adoption of our products.”
Elizabeth Smith has more than 20 years of experience in pre-clinical testing, pre-approval regulated trials, post-launch clinical evaluations, and compliant marketing. She previously served as Senior Director, Clinical Research at AgNovos Healthcare, a start-up orthopedic company. She has held clinical management positions at a range of medical device companies including K2M, Zimmer, Inc., St. Jude Medical, and American Medical Systems.
“It is pivotal time for ACell, and the addition of strong talent like Elizabeth elevates our ability to execute world-class clinical programs.” said Thomas Gilbert, Ph.D., Chief Science Officer. “ACell has an increasing number of research projects in progress to support our corporate growth strategies, and I am confident that Elizabeth will effectively oversee these efforts.”
About ACell, Inc.
ACell, Inc. is a leading regenerative medicine company focused on the development, manufacturing and commercialization of unique proprietary extracellular matrix (ECM) products to facilitate the repair and remodeling of damaged tissues. ACell is committed to becoming and remaining an innovative leader in regenerative medical technology, offering superior healing options for doctors and patients. ACell is a privately held company and operates manufacturing facilities in Columbia, MD and Lafayette, IN. For more information, call 800-826-2926 or visit www.acell.com.
MatriStem products contain the epithelial basement membrane from porcine urinary bladder, and are based on the proprietary ECM composition generally referred to in scientific literature as urinary bladder matrix, or UBM. UBM is a segment of tissue layers that facilitates a constructive tissue remodeling response by the patient’s body. MatriStem products are indicated for use in general surgery, gynecological surgery, and in the management of a wide range of wounds. Refer to the IFU supplied with each product for indications, contraindications and precautions. All MatriStem products are made in the USA.Return to News